FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2414395973> ?p ?o ?g. }

• W2414395973 endingPage "e316" @default.
• W2414395973 startingPage "e309" @default.
• W2414395973 abstract "Background The PI3K–mTORC pathway is upregulated in diffuse large B-cell lymphoma (DLBCL) and can be targeted with the mTOR complex 1 (mTORC1) inhibitor everolimus. Everolimus has activity in relapsed DLBCL. These data provide the rationale to combine everolimus with standard treatment for DLBCL of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone delivered in a 21-day cycle (R-CHOP-21) for six cycles. Methods We did a phase 1 and feasibility study (NCCTG 1085) of oral everolimus 10 mg/day plus R-CHOP-21 in patients aged at least 18 years with new, untreated, CD20-positive DLBCL (stages II–IV) in the NCCTG (Alliance) National Cancer Institute Cooperative Group (USA). Patients received standard R-CHOP-21 (intravenous rituximab 375 mg/m2, intravenous cyclophosphamide 750 mg/m2, intravenous doxorubicin 50 mg/m2, and intravenous vincristine 1·4 mg/m2 [maximum 2·0 mg] all on day 1 of the 21-day cycle; and oral prednisone 100 mg/m2 each day on days 1–5 of the cycle) for six cycles with scheduled subcutaneous pegfilgrastim 6 mg on day 2 of each cycle. We tested two schedules: everolimus given in the fasting state either on days 1–10 or days 1–14 of the R-CHOP cycle. The primary endpoint of the phase 1 portion of this study was to establish the maximum tolerated dose of everolimus that could be combined with R-CHOP-21. The primary endpoint of the feasibility portion of the study was to determine the feasibility of the regimen, which was assessed by determining the rate of significant toxicity. Secondary endpoints were the proportion of patients who achieved an overall response, a complete response, event-free survival at 12 months and 24 months from enrolment, progression-free survival, and overall survival; relapse of DLBCL; and duration of response. We deemed patients as assessable for the primary endpoint in the phase 1 portion if they completed the first cycle as planned. In the feasibility portion, all patients who received at least one dose of everolimus were included. This trial is registered with ClinicalTrials.gov, number NCT01334502. Findings Between March 21, 2012, and Sept 15, 2014, we enrolled 26 patients into the study. Two were ineligible, therefore results are presented for 24 eligible patients. Nine patients were enrolled into the phase 1 portion of the trial (three given everolimus on days 1–10, and six given everolimus on days 1–14) without any dose-limiting toxicities; therefore, everolimus 10 mg/day given on days 1–14 with R-CHOP-21 was tested in 15 additional patients for a total of 24. One (5%, 95% CI 0–24%) of 21 patients had a toxicity during the feasibility phase—a treatment delay of 12 days due to grade 3 hypokalaemia possibly related to everolimus. The median follow-up was 21·5 months (IQR 17–29). 23 (96%, 95% CI 79–100%) of 24 patients achieved an overall response, and all 23 (96%, 79–100%) also attained a complete metabolic response by PET. The remaining patient withdrew consent after in cycle 1 and attained a complete response with R-CHOP alone. All 24 (100%) patients met 12-month event-free survival, and nine had sufficient follow-up data to be event-free at 24 months. None of the 24 patients had died by the last follow-up (March 30, 2016), and none had had a relapse with DLBCL. Because no events occurred during the study or follow-up, we were unable to assess the duration of response or progression-free survival. The most common grade 3–4 adverse events were haematological; the most common of these was grade 4 neutropenia in 18 (75%) of 24 patients. Five (21%) of 24 had grade 3 febrile neutropenia. Interpretation The mTORC1 inhibitor everolimus given for 14 days in combination with R-CHOP-21 for patients with DLBCL is safe. These findings suggest that drugs that target the PI3K–mTORC pathway add benefit when combined with standard R-CHOP. The everolimus with R-CHOP regimen should be tested against standard R-CHOP alone in a randomised trial, to support the benefits of this novel combination noted in this study. Funding National Cancer Institute of the US National Institutes of Health. The PI3K–mTORC pathway is upregulated in diffuse large B-cell lymphoma (DLBCL) and can be targeted with the mTOR complex 1 (mTORC1) inhibitor everolimus. Everolimus has activity in relapsed DLBCL. These data provide the rationale to combine everolimus with standard treatment for DLBCL of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone delivered in a 21-day cycle (R-CHOP-21) for six cycles. We did a phase 1 and feasibility study (NCCTG 1085) of oral everolimus 10 mg/day plus R-CHOP-21 in patients aged at least 18 years with new, untreated, CD20-positive DLBCL (stages II–IV) in the NCCTG (Alliance) National Cancer Institute Cooperative Group (USA). Patients received standard R-CHOP-21 (intravenous rituximab 375 mg/m2, intravenous cyclophosphamide 750 mg/m2, intravenous doxorubicin 50 mg/m2, and intravenous vincristine 1·4 mg/m2 [maximum 2·0 mg] all on day 1 of the 21-day cycle; and oral prednisone 100 mg/m2 each day on days 1–5 of the cycle) for six cycles with scheduled subcutaneous pegfilgrastim 6 mg on day 2 of each cycle. We tested two schedules: everolimus given in the fasting state either on days 1–10 or days 1–14 of the R-CHOP cycle. The primary endpoint of the phase 1 portion of this study was to establish the maximum tolerated dose of everolimus that could be combined with R-CHOP-21. The primary endpoint of the feasibility portion of the study was to determine the feasibility of the regimen, which was assessed by determining the rate of significant toxicity. Secondary endpoints were the proportion of patients who achieved an overall response, a complete response, event-free survival at 12 months and 24 months from enrolment, progression-free survival, and overall survival; relapse of DLBCL; and duration of response. We deemed patients as assessable for the primary endpoint in the phase 1 portion if they completed the first cycle as planned. In the feasibility portion, all patients who received at least one dose of everolimus were included. This trial is registered with ClinicalTrials.gov, number NCT01334502. Between March 21, 2012, and Sept 15, 2014, we enrolled 26 patients into the study. Two were ineligible, therefore results are presented for 24 eligible patients. Nine patients were enrolled into the phase 1 portion of the trial (three given everolimus on days 1–10, and six given everolimus on days 1–14) without any dose-limiting toxicities; therefore, everolimus 10 mg/day given on days 1–14 with R-CHOP-21 was tested in 15 additional patients for a total of 24. One (5%, 95% CI 0–24%) of 21 patients had a toxicity during the feasibility phase—a treatment delay of 12 days due to grade 3 hypokalaemia possibly related to everolimus. The median follow-up was 21·5 months (IQR 17–29). 23 (96%, 95% CI 79–100%) of 24 patients achieved an overall response, and all 23 (96%, 79–100%) also attained a complete metabolic response by PET. The remaining patient withdrew consent after in cycle 1 and attained a complete response with R-CHOP alone. All 24 (100%) patients met 12-month event-free survival, and nine had sufficient follow-up data to be event-free at 24 months. None of the 24 patients had died by the last follow-up (March 30, 2016), and none had had a relapse with DLBCL. Because no events occurred during the study or follow-up, we were unable to assess the duration of response or progression-free survival. The most common grade 3–4 adverse events were haematological; the most common of these was grade 4 neutropenia in 18 (75%) of 24 patients. Five (21%) of 24 had grade 3 febrile neutropenia. The mTORC1 inhibitor everolimus given for 14 days in combination with R-CHOP-21 for patients with DLBCL is safe. These findings suggest that drugs that target the PI3K–mTORC pathway add benefit when combined with standard R-CHOP. The everolimus with R-CHOP regimen should be tested against standard R-CHOP alone in a randomised trial, to support the benefits of this novel combination noted in this study." @default.
• W2414395973 created "2016-06-24" @default.
• W2414395973 creator A5004152557 @default.
• W2414395973 creator A5025688165 @default.
• W2414395973 creator A5044733637 @default.
• W2414395973 creator A5048644166 @default.
• W2414395973 creator A5059729547 @default.
• W2414395973 creator A5061713890 @default.
• W2414395973 creator A5064576471 @default.
• W2414395973 creator A5071201232 @default.
• W2414395973 creator A5076892547 @default.
• W2414395973 creator A5082655055 @default.
• W2414395973 date "2016-07-01" @default.
• W2414395973 modified "2023-10-01" @default.
• W2414395973 title "Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial" @default.
• W2414395973 cites W1020989877 @default.
• W2414395973 cites W1094999820 @default.
• W2414395973 cites W1974816429 @default.
• W2414395973 cites W1977824829 @default.
• W2414395973 cites W1983441975 @default.
• W2414395973 cites W1988805574 @default.
• W2414395973 cites W2013811004 @default.
• W2414395973 cites W2015973524 @default.
• W2414395973 cites W2019874087 @default.
• W2414395973 cites W2044306036 @default.
• W2414395973 cites W2054917860 @default.
• W2414395973 cites W2058015212 @default.
• W2414395973 cites W2062424910 @default.
• W2414395973 cites W2062457956 @default.
• W2414395973 cites W2067257663 @default.
• W2414395973 cites W2087078179 @default.
• W2414395973 cites W2111530307 @default.
• W2414395973 cites W2131940231 @default.
• W2414395973 cites W2133201432 @default.
• W2414395973 cites W2134861285 @default.
• W2414395973 cites W2135426730 @default.
• W2414395973 cites W2136268782 @default.
• W2414395973 cites W2137235604 @default.
• W2414395973 cites W2139836848 @default.
• W2414395973 cites W2141127172 @default.
• W2414395973 cites W2147246240 @default.
• W2414395973 cites W2153665789 @default.
• W2414395973 cites W2161965680 @default.
• W2414395973 cites W2167556523 @default.
• W2414395973 cites W2171356556 @default.
• W2414395973 cites W4293241248 @default.
• W2414395973 doi "https://doi.org/10.1016/s2352-3026(16)30040-0" @default.
• W2414395973 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4958393" @default.
• W2414395973 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27374464" @default.
• W2414395973 hasPublicationYear "2016" @default.
• W2414395973 type Work @default.
• W2414395973 sameAs 2414395973 @default.
• W2414395973 citedByCount "48" @default.
• W2414395973 countsByYear W24143959732016 @default.
• W2414395973 countsByYear W24143959732017 @default.
• W2414395973 countsByYear W24143959732018 @default.
• W2414395973 countsByYear W24143959732019 @default.
• W2414395973 countsByYear W24143959732020 @default.
• W2414395973 countsByYear W24143959732021 @default.
• W2414395973 countsByYear W24143959732022 @default.
• W2414395973 countsByYear W24143959732023 @default.
• W2414395973 crossrefType "journal-article" @default.
• W2414395973 hasAuthorship W2414395973A5004152557 @default.
• W2414395973 hasAuthorship W2414395973A5025688165 @default.
• W2414395973 hasAuthorship W2414395973A5044733637 @default.
• W2414395973 hasAuthorship W2414395973A5048644166 @default.
• W2414395973 hasAuthorship W2414395973A5059729547 @default.
• W2414395973 hasAuthorship W2414395973A5061713890 @default.
• W2414395973 hasAuthorship W2414395973A5064576471 @default.
• W2414395973 hasAuthorship W2414395973A5071201232 @default.
• W2414395973 hasAuthorship W2414395973A5076892547 @default.
• W2414395973 hasAuthorship W2414395973A5082655055 @default.
• W2414395973 hasBestOaLocation W24143959732 @default.
• W2414395973 hasConcept C126322002 @default.
• W2414395973 hasConcept C143998085 @default.
• W2414395973 hasConcept C197934379 @default.
• W2414395973 hasConcept C2778559949 @default.
• W2414395973 hasConcept C2779338263 @default.
• W2414395973 hasConcept C2779699572 @default.
• W2414395973 hasConcept C2779725641 @default.
• W2414395973 hasConcept C3018359032 @default.
• W2414395973 hasConcept C31760486 @default.
• W2414395973 hasConcept C535046627 @default.
• W2414395973 hasConcept C71924100 @default.
• W2414395973 hasConceptScore W2414395973C126322002 @default.
• W2414395973 hasConceptScore W2414395973C143998085 @default.
• W2414395973 hasConceptScore W2414395973C197934379 @default.
• W2414395973 hasConceptScore W2414395973C2778559949 @default.
• W2414395973 hasConceptScore W2414395973C2779338263 @default.
• W2414395973 hasConceptScore W2414395973C2779699572 @default.
• W2414395973 hasConceptScore W2414395973C2779725641 @default.
• W2414395973 hasConceptScore W2414395973C3018359032 @default.
• W2414395973 hasConceptScore W2414395973C31760486 @default.
• W2414395973 hasConceptScore W2414395973C535046627 @default.
• W2414395973 hasConceptScore W2414395973C71924100 @default.
• W2414395973 hasIssue "7" @default.
• W2414395973 hasLocation W24143959731 @default.
• W2414395973 hasLocation W24143959732 @default.

• next